Benchmarking is associated with improved quality of care in type 2 diabetes: the OPTIMISE randomized, controlled trial

Michel P Hermans, Moses Elisaf, Georges Michel, Erik Muls, Frank Nobels, Hans Vandenberghe, Carlos Brotons, OPTIMISE International Steering Committee, Michel P Hermans, Moses Elisaf, Georges Michel, Erik Muls, Frank Nobels, Hans Vandenberghe, Carlos Brotons, OPTIMISE International Steering Committee

Abstract

Objective: To assess prospectively the effect of benchmarking on quality of primary care for patients with type 2 diabetes by using three major modifiable cardiovascular risk factors as critical quality indicators.

Research design and methods: Primary care physicians treating patients with type 2 diabetes in six European countries were randomized to give standard care (control group) or standard care with feedback benchmarked against other centers in each country (benchmarking group). In both groups, laboratory tests were performed every 4 months. The primary end point was the percentage of patients achieving preset targets of the critical quality indicators HbA1c, LDL cholesterol, and systolic blood pressure (SBP) after 12 months of follow-up.

Results: Of 4,027 patients enrolled, 3,996 patients were evaluable and 3,487 completed 12 months of follow-up. Primary end point of HbA1c target was achieved in the benchmarking group by 58.9 vs. 62.1% in the control group (P = 0.398) after 12 months; 40.0 vs. 30.1% patients met the SBP target (P < 0.001); 54.3 vs. 49.7% met the LDL cholesterol target (P = 0.006). Percentages of patients meeting all three targets increased during the study in both groups, with a statistically significant increase observed in the benchmarking group. The percentage of patients achieving all three targets at month 12 was significantly larger in the benchmarking group than in the control group (12.5 vs. 8.1%; P < 0.001).

Conclusions: In this prospective, randomized, controlled study, benchmarking was shown to be an effective tool for increasing achievement of critical quality indicators and potentially reducing patient cardiovascular residual risk profile.

Trial registration: ClinicalTrials.gov NCT00681850.

Figures

Figure 1
Figure 1
Patient disposition.
Figure 2
Figure 2
Percentages of patients reaching critical quality indicator targets at baseline and after 12 months of follow-up. A: HbA1c target <7.0% (<53.0 mmol/mol). B: SBP target <130 mmHg (<125 mmHg in patients with proteinuria). C: LDL cholesterol target <100 mg/dL (<80 mg/dL in Belgium; <70 mg/dL in patients with existing CHD). D: Percentages of patients reaching target for all three critical quality indicators.

References

    1. International Diabetes Federation. IDF Diabetes Atlas 5th edition [Internet], 2011. Brussels, International Diabetes Federation. Available from Accessed 12 December 2011
    1. International Diabetes Federation. IDF Diabetes Atlas 4th edition [Internet], 2009. Brussels, International Diabetes Federation. Available from Accessed 12 December 2011
    1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837–853
    1. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703–713
    1. Turnbull F, Neal B, Algert C, et al. Blood Pressure Lowering Treatment Trialists’ Collaboration Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005;165:1410–1419
    1. Pyŏrälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614–620
    1. Goldberg RB, Mellies MJ, Sacks FM, et al. The Care Investigators Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 1998;98:2513–2519
    1. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999;159:2661–2667
    1. Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–2559
    1. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–2572
    1. Serrano-Gil M, Jacob S. Engaging and empowering patients to manage their type 2 diabetes, Part I: a knowledge, attitude, and practice gap? Adv Ther 2010;27:321–333
    1. Kiefe CI, Allison JJ, Williams OD, Person SD, Weaver MT, Weissman NW. Improving quality improvement using achievable benchmarks for physician feedback: a randomized controlled trial. JAMA 2001;285:2871–2879
    1. O’Connor PJ, Sperl-Hillen J, Johnson PE, Rush WA, Crain AL. Customized feedback to patients and providers failed to improve safety or quality of diabetes care: a randomized trial. Diabetes Care 2009;32:1158–1163
    1. Pape GA, Hunt JS, Butler KL, et al. Team-based care approach to cholesterol management in diabetes mellitus: two-year cluster randomized controlled trial. Arch Intern Med 2011;171:1480–1486
    1. Nobels F, Debacker N, Brotons C, et al. OPTIMISE (OPtimal Type 2 dIabetes Management Including benchmarking and Standard trEatment) International Steering Committee Study rationale and design of OPTIMISE, a randomised controlled trial on the effect of benchmarking on quality of care in type 2 diabetes mellitus. Cardiovasc Diabetol 2011;10:82.
    1. Hermans MP, Brotons C, Elisaf M , Michel G, Muls E, Nobels F. Optimal type 2 diabetes mellitus management: the randomized controlled OPTIMISE benchmarking study: baseline results from six European countries. Eur J Prev Cardiol. 17 May 2012 [Epub ahead of print]
    1. Conroy RM, Pyörälä K, Fitzgerald AP, et al. SCORE project group Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987–1003
    1. Reiner Z, Catapano AL, De Backer G, et al. European Association for Cardiovascular Prevention & Rehabilitation. ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769–1818
    1. Brohet C, De Backer G, Scheen AJ, Van Gaal LF, Duquenne V, Vissers E. Belgian evaluation of screening and treatment of high-risk patients based on waist and age (Best study) (Abstract). Eur J Cardiac Prev Rehabil 2005;12:280
    1. Machin D, Campbell M, Fayers P, Pinol A. Sample Size Tables for Clinical Studies. Oxford, Blackwell Science, 1997
    1. Lachin JM. Biostatistical Methods. New York, John Wiley & Sons, 2002
    1. Eccles MP, Whitty PM, Speed C, et al. A pragmatic cluster randomised controlled trial of a Diabetes REcall And Management system: the DREAM trial. Implement Sci 2007;2:6.
    1. de Pablos-Velasco P, Bradley C, Eschwège E, et al. The PANORAMA pan-European survey: glycaemic control and treatment patterns in patients with type 2 diabetes (Abstract). Diabetologia 2010;53(Suppl. 1):S405
    1. McCrate F, Godwin M, Murphy L. Attainment of Canadian Diabetes Association recommended targets in patients with type 2 diabetes: a study of primary care practices in St John’s, Nfld. Can Fam Physician 2010;56:e13–e19
    1. Kuznik A, Mardekian J. Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008. Cardiovasc Diabetol 2011;10:31.
    1. Wens J, Gerard R, Vandenberghe H. Optimizing diabetes care regarding cardiovascular targets at general practice level: Direct@GP. Prim Care Diabetes 2011;5:19–24
    1. Hermans MP, Ahn SA, Rousseau MF. Residual vascular risk in T2DM: the next frontier. In Recent Advances in the Pathogenesis, Prevention and Management of Type 2 Diabetes and Its Complications. Zimering M, Ed. Rijeka, Croatia, InTech, 2011, p. 45–66
    1. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med 2001;135:825–834
    1. van Bruggen R, Gorter K, Stolk R, Klungel O, Rutten G. Clinical inertia in general practice: widespread and related to the outcome of diabetes care. Fam Pract 2009;26:428–436
    1. Nelson SA, Dresser GK, Vandervoort MK, et al. Barriers to blood pressure control: a STITCH substudy. J Clin Hypertens (Greenwich) 2011;13:73–80
    1. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005–2012
    1. Morrison F, Shubina M, Turchin A. Encounter frequency and serum glucose level, blood pressure, and cholesterol level control in patients with diabetes mellitus. Arch Intern Med 2011;171:1542–1550
    1. Zhang SL, Chen ZC, Yan L, Chen LH, Cheng H, Ji LN. Determinants for inadequate glycaemic control in Chinese patients with mild-to-moderate type 2 diabetes on oral antidiabetic drugs alone. Chin Med J (Engl) 2011;124:2461–2468
    1. Ebrahim S. Detection, adherence and control of hypertension for the prevention of stroke: a systematic review. Health Technol Assess 1998;2:i–iv, 1–78
    1. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006;19:1190–1196
    1. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007;167:540–550
    1. Jamtvedt G, Young JM, Kristoffersen DT, O’Brien MA, Oxman AD. Does telling people what they have been doing change what they do? A systematic review of the effects of audit and feedback. Qual Saf Health Care 2006;15:433–436
    1. Hysong SJ. Meta-analysis: audit and feedback features impact effectiveness on care quality. Med Care 2009;47:356–363
    1. Roethlisberger FJ, Dickson WJ. Management and the worker. Cambridge, MA, Harvard Univ. Press, 1939
    1. McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne Effect: a randomised, controlled trial. BMC Med Res Methodol 2007;7:30.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren